Protocol for the PACE trial: A randomised controlled trial of adaptive pacing, cognitive behaviour therapy, and graded exercise as supplements to standardised specialist medical care versus standardised specialist medical care alone for patients with the chronic fatigue syndrome/myalgic encephalomyelitis or encephalopathy by White, Peter D et al.
BioMed  Central
Page 1 of 20
(page number not for citation purposes)
BMC Neurology
Open Access Study protocol
Protocol for the PACE trial: A randomised controlled trial of 
adaptive pacing, cognitive behaviour therapy, and graded exercise 
as supplements to standardised specialist medical care versus 
standardised specialist medical care alone for patients with the 
chronic fatigue syndrome/myalgic encephalomyelitis or 
encephalopathy
Peter D White*1, Michael C Sharpe2, Trudie Chalder3, Julia C DeCesare4, 
Rebecca Walwyn5 and the PACE trial group4
Address: 1Department of Psychological Medicine, Queen Mary School of Medicine and Dentistry, St Bartholomew's Hospital, London, UK, 
2Psychological Medicine and Symptoms Research Group, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, Scotland, UK, 
3Academic Department of Psychological Medicine, Guy's, King's and St Thomas' School of Medicine, Weston Education Centre, London, UK, 
4PACE Trial Coordinating Centre, Queen Mary School of Medicine and Dentistry, St Bartholomew's Hospital, London, UK and 5Mental Health & 
Neuroscience Clinical Trials Unit (MH&N CTU), Institute of Psychiatry, London, UK
Email: Peter D White* - p.d.white@qmul.ac.uk; Michael C Sharpe - michael.sharpe@ed.ac.uk; Trudie Chalder - t.chalder@iop.kcl.ac.uk; 
Julia C DeCesare - j.c.decesare@qmul.ac.uk; Rebecca Walwyn - R.Walwyn@iop.kcl.ac.uk; the PACE trial group - pace@qmul.ac.uk
* Corresponding author    
Abstract
Background:  Chronic fatigue syndrome (CFS, also called myalgic encephalomyelitis/encephalopathy or ME) is a
debilitating condition with no known cause or cure. Improvement may occur with medical care and additional therapies
of pacing, cognitive behavioural therapy and graded exercise therapy. The latter two therapies have been found to be
efficacious in small trials, but patient organisations' surveys have reported adverse effects. Although pacing has been
advocated by patient organisations, it lacks empirical support. Specialist medical care is commonly provided but its
efficacy when given alone is not established. This trial compares the efficacy of the additional therapies when added to
specialist medical care against specialist medical care alone.
Methods/Design: 600 patients, who meet operationalised diagnostic criteria for CFS, will be recruited from secondary
care into a randomised trial of four treatments, stratified by current comorbid depressive episode and different CFS/ME
criteria. The four treatments are standardised specialist medical care either given alone, or with adaptive pacing therapy
or cognitive behaviour therapy or graded exercise therapy. Supplementary therapies will involve fourteen sessions over
23 weeks and a 'booster session' at 36 weeks. Outcome will be assessed at 12, 24, and 52 weeks after randomisation.
Two primary outcomes of self-rated fatigue and physical function will assess differential effects of each treatment on these
measures. Secondary outcomes include adverse events and reactions, subjective measures of symptoms, mood, sleep and
function and objective measures of physical activity, fitness, cost-effectiveness and cost-utility. The primary analysis will
be based on intention to treat and will use logistic regression models to compare treatments. Secondary outcomes will
be analysed by repeated measures analysis of variance with a linear mixed model. All analyses will allow for stratification
factors. Mediators and moderators will be explored using multiple linear and logistic regression techniques with
interactive terms, with the sample split into two to allow validation of the initial models. Economic analyses will
incorporate sensitivity measures.
Published: 8 March 2007
BMC Neurology 2007, 7:6 doi:10.1186/1471-2377-7-6
Received: 30 October 2006
Accepted: 8 March 2007
This article is available from: http://www.biomedcentral.com/1471-2377/7/6
© 2007 White et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Neurology 2007, 7:6 http://www.biomedcentral.com/1471-2377/7/6
Page 2 of 20
(page number not for citation purposes)
Discussion: The results of the trial will provide information about the benefits and adverse effects of these treatments,
their cost-effectiveness and cost-utility, the process of clinical improvement and the predictors of efficacy.
Background
Introduction
The chronic fatigue syndrome (CFS) is a condition charac-
terised by chronic disabling fatigue and other symptoms,
which are not better explained by an alternative diagnosis
[1-3]. Myalgic encephalomyelitis/encephalopathy (ME)
refers to a severe debilitating illness thought by some to be
a separate illness, but by others to be synonymous with
CFS [2-6]. In keeping with the MRC Research Advisory
Group report and the CMO's working group report, we
will refer to the illness using both terms: CFS/ME [4,6].
The prevalence of CFS/ME in the population is between
0.4 and 2.5% [3,4,6]. A working group, reporting to the
Chief Medical Officer (CMO) for England, concluded;
"CFS/ME is a relatively common clinical condition, which
can cause profound, often prolonged, illness and disabil-
ity, and can have a substantial impact on the individual
and the family" [4]. As many as half the patients with CFS/
ME are unemployed [7], and they have 10 times the
amount of sick-leave of other general medical outpatients
[8]. The prognosis is poor: in primary care only a third
improve by one year, and of those referred to secondary
care less than 10% return to pre-morbid functioning [3,9].
The management of patients with CFS/ME currently con-
sumes significant resources in both primary and second-
ary care with uncertain benefit to patients [4,5]. CFS/ME
patients use an annual average of 13 visits to their general
practitioner and 5 visits to secondary care [7]. There is
now some evidence that specific treatments can improve
these poor outcomes. The CMO's working group con-
cluded; "Therapeutic strategies that can enable improve-
ment include graded exercise/activity programmes,
cognitive behaviour therapy, and pacing" [4]. However
this positive statement was balanced in the report by other
statements: first the concern of patient organisations that
graded exercise therapy (GET) may sometimes worsen
symptoms and disability, and second that pacing,
although widely advocated by patients' organisations, is
as yet unsupported by scientific evidence.
Efficacy – Relevant studies/trials
Two independent systematic reviews have found that
rehabilitative cognitive behaviour therapy (CBT) and GET
were the most promising treatments for CFS/ME in sec-
ondary care [5,10-12]. The published trials of these treat-
ments were however also criticized for being too small,
too selective, and for using different outcome measures.
No other treatments for CFS/ME have so far been shown
to be helpful in more than one RCT [5,12]. CBT is a more
complex therapy than GET, requiring highly trained ther-
apists, and is therefore less readily available. In contrast,
surveys carried out by Action for M.E. of their members
have indicated that CBT and GET can sometimes make
people worse [13-15]. Pacing and rest were reported to be
more helpful [13]. Pacing has been described in the scien-
tific literature as a lifestyle management that allows opti-
mal adaptation to the illness, including an appropriate
balance of rest and activity [4,16]. It has been advocated
by exponents of the "envelope theory" of CFS/ME, which
states that a patient has a fixed and finite amount, or
"envelope", of energy that they must adapt to by manag-
ing their activity [16]. A non-randomised comparison of
adaptive (rather than rehabilitative) CBT, which included
adaptive pacing therapy (APT) based on this model,
found that, although fatigue improved, this treatment was
no more effective than the control treatment in reducing
disability [17]. A recent systematic review concluded that
there was insufficient evidence to recommend APT at
present [5,10,12]. In a similar way there is little RCT evi-
dence of the efficacy of specialist medical care. There is
therefore an urgent need to: (a) compare the supplemen-
tary therapies of both CBT and GET with both APT and
standardised specialist medical care (SSMC) alone, seek-
ing evidence of both benefit and harm (b) compare sup-
plementary APT against SSMC alone and (c) compare the
supplementary therapies of APT, CBT and GET in order to
clarify differential predictors and mechanisms of change.
Differential outcomes
Because CBT and GET are both based on a graded expo-
sure to activity, they may preferentially reduce disability,
whilst APT, being based on the theory that one must stay
within the limits of a finite amount of "energy", may
reduce symptoms, but at the expense of not reducing dis-
ability. By measuring both symptoms and disability as our
primary outcomes, we will be able to test a secondary
hypothesis that these treatments may differentially affect
symptoms and disability.
Process of treatment
We do not know the mechanisms of successful treatment
for CFS/ME. Do illness beliefs or focusing of attention on
symptoms (symptom focusing) need to be changed for
CBT to be effective? Or do CBT and GET both work by
improving tolerance to activity? Is increased physical fit-
ness essential to recovery or not? How important is the
alliance between therapist and patient? Is it necessary to
adapt to the limitations imposed by the illness to reduce
fatigue? A greater understanding of these processes willBMC Neurology 2007, 7:6 http://www.biomedcentral.com/1471-2377/7/6
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shed light on the essence of improvement and allow the
development of more efficient treatments.
Predictors of outcome
Predictors of a negative response to treatment found in
previous studies include having a mood disorder, mem-
bership of a self-help group, being in receipt of a disability
pension, focusing on physical symptoms, and pervasive
inactivity [3,18,19]. There is however no general agree-
ment on which are the most important predictive factors.
Cost-effectiveness and cost utility
A recent study has suggested that there is little difference
in the cost-effectiveness of CBT and GET for chronic
fatigue in primary care, and both were more expensive and
more effective than standard care [20]. However, only
one-third of patients in this study had CFS/ME and it was
not powered to detect differences for this subgroup. There
are currently only limited published data on the cost-
effectiveness of treatments specifically for CFS/ME.
Risks and benefits
There is a discrepancy between surveys of CFS/ME patient
group members and published evidence from trials. Some
CFS/ME charity members have reported that they feel
worse after exercise therapy, and to a lesser extent CBT
[13,14], whereas the trial evidence suggests minimal or no
risk with these treatments. A further survey by Action for
M.E. of their members suggests that reports of deteriora-
tion with therapy are related to either poorly administered
treatment or lack of appropriate professional supervision
[15]. The individual treatment programmes used in PACE
will minimise this risk by being mutually agreed between
participant and therapist, carefully monitored and flexibly
implemented. We will also carefully monitor all partici-
pants for any adverse effects of the treatments, and will
undertake a detailed assessment, at home if necessary, of
any participant who reports deterioration or who with-
draws from treatment, following which they will be
offered appropriate help.
Rationale
The results of this trial will: (a) allow people with CFS/
ME, clinicians and health planners to choose treatment on
the basis of both efficacy and cost; (b) provide evidence
about the efficacy and adverse effects of the four treat-
ments (APT, CBT, GET and SSMC); (c) provide the first
test of SSMC plus pacing against SSMC alone; (d) indicate
which patient characteristics predict a successful outcome;
(e) identify which patient characteristics predict response
to which treatment and (f) define the essential aspects of
effective treatment as a first step toward the development
of more efficient therapies.
The trial will recruit new patients from secondary care
clinics run by three different disciplines (immunology,
infectious disease and psychiatry) in six different centres
in both England and Scotland. This recruitment plan will
ensure sufficient heterogeneity to allow generalisation of
the findings. We will not recruit directly from primary care
because we wish to compare the efficacy of these treat-
ments in patients whom GPs regard as requiring addi-
tional help and who are likely to have a worse prognosis
(one of the recommendations CMO's report [4]). Further-
more, direct recruitment from primary care has been
found to be problematic in previous studies. Two recent
trials of treatment for prolonged fatigue (not CFS/ME)
using large and well established primary care research net-
works recruited only 46 patients with CFS/ME in three
years [21] and 44 patients in 2.5 years [22].
Methods/Design
Aims
The main aim of this trial is to provide high quality evi-
dence to inform choices made by patients, patient organ-
isations, health services and health professionals about
the relative benefits, cost-effectiveness, and cost-utility, as
well as adverse effects, of the most widely advocated treat-
ments for CFS/ME.
The secondary aims of this trial are to investigate the
mechanisms and predictors of a successful outcome.
Objectives
The PACE trial is designed to answer the following ques-
tions:
Primary objectives
(1) Is APT and SSMC more effective than SSMC alone in
reducing (i) fatigue, (ii) disability, or (iii) both?
(2) Is CBT and SSMC more effective than APT and SSMC
in reducing (i) fatigue, (ii) disability or (iii) both?
(3) Is GET and SSMC more effective than APT and SSMC
in reducing (i) fatigue, (ii) disability, or (iii) both?
(4) Are the active rehabilitation therapies (of either CBT or
GET) more effective than the adaptive approach of APT
when each is added to SSMC, in reducing (i) fatigue and/
or (ii) disability?
(5) What are the relative cost-effectiveness and cost-utility
of these treatments?
NB For the sake of brevity, the rest of the protocol will refer to
the four treatment arms as APT, CBT, GET and SSMC rather
than APT plus SSMC, CBT plus SSMC, GET plus SSMC and
SSMC alone.BMC Neurology 2007, 7:6 http://www.biomedcentral.com/1471-2377/7/6
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Secondary objectives
The secondary analyses are exploratory but we will be
guided by previously published findings.
(1) Do different treatments have differential effects on
outcomes (i.e. fatigue versus physical disability)?
(2) What baseline factors (other than randomised treat-
ment) predict a reduction in (i) fatigue, (ii) disability in
all participants?
(3) Are there differential predictors of response to APT,
CBT, GET, and SSMC (i.e. treatment-covariate interac-
tions)?
(4) Are there changes in factors (time-dependent covari-
ates) during the earlier stages of treatment that (after con-
trolling for baseline overall and differential predictors) are
associated with outcome 1 year after randomisation?
(5) Are the differences across treatment groups in the pri-
mary outcomes associated with similar differences in sec-
ondary outcomes (e.g. in global change, mood, quality of
life and objective measures of physical activity)?
Hypotheses of efficacy
(1) APT is more effective than SSMC alone in reducing (i)
fatigue, (ii) reducing physical disability and in reducing
(iii) both.
(2) CBT is more effective than APT in reducing (i) fatigue,
(ii) disability and in reducing (iii) both
(3) GET is more effective than APT in reducing (i) fatigue,
(ii) disability and in reducing (iii) both
(4) The active rehabilitation therapies (of either CBT or
GET) are more effective than the adaptive approach of APT
in reducing fatigue, physical disability and both
(5) CBT is more effective than SSMC in reducing (i)
fatigue, (ii) disability and in reducing (iii) both
(6) GET is more effective than SSMC in reducing (i)
fatigue, (ii) disability and in reducing (iii) both
Other secondary hypotheses will be stated pre-hoc in an
Analysis Strategy document.
Type of design
A four arm, randomised multi-centre parallel group con-
trolled trial of patients who meet operationalised criteria
for CFS/ME, with follow-up for 52 weeks (see Figure 1).
Trial treatments – interventions and control
There are four treatment arms. SSMC is given to all partic-
ipants. Three quarters will also receive one of the follow-
ing supplementary therapies: APT, CBT or GET.
Duration
Patients will be assessed for eligibility and those who are
eligible and give consent will be randomly allocated to
one of four treatments. Treatment will start as soon as pos-
sible after randomisation. The final outcome assessment
will be at 52 weeks post randomisation.
Number and source of participants
We will study 600 participants, recruited from new patient
attenders, over approximately three years in six centres. All
participants will be attending secondary care chronic
fatigue clinics.
All centres have reported that they currently see a mini-
mum of 100 new patients per year. We estimate that 60
will meet eligibility criteria, and we estimate that two
thirds of these will agree to enter the trial, giving poten-
tially a minimum of 40 participants per centre. In previ-
ous trials of both CBT and GET, only 7 and 15% of eligible
participants refused to participate in GET trials [23,24]
and 3, 10 and 26% of those eligible refused to participate
in the three previous CBT trials [18,25,26]. We are there-
fore confident that recruitment is feasible and that the
trial will recruit 600 participants over three years.
Projected recruitment
Recruitment estimates are based upon 80% efficiency for
the first three months rising to 100% efficiency by six
months.
Inclusion criteria
1. Both participant and clinician agree that randomisation
is acceptable.
2. The participant has given written informed consent.
3. The participant meets operationalised Oxford research
diagnostic criteria for CFS [2].
4. The participant's Chalder Fatigue Questionnaire score is
6 or more [27].
5. The participant's SF-36 physical function sub-scale
score [28] is 65 or less.
6. The participant is aged at least 18 years old.
Exclusion criteria
1. All potential participants will be screened for medical
exclusions, by history and physical examinationBMC Neurology 2007, 7:6 http://www.biomedcentral.com/1471-2377/7/6
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Table 1: Flowchart of trial design Figure 1
Table 1: Flowchart of trial design.BMC Neurology 2007, 7:6 http://www.biomedcentral.com/1471-2377/7/6
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[1,2,4,29]. Appropriate investigations [4,29] will be
undertaken by either the referring doctor or the centre
doctors (checked by the research nurse) in the six months
before baseline screening. Patients with a relevant alterna-
tive medical diagnosis will be excluded [2]. Investigations
will be those recommended by the Royal Colleges' Report
on CFS/ME and the CMO's working group report [4,29].
2. The research nurse (RN) will use a standardised psychi-
atric interview (the Structured Clinical Interview for DSM-
IV – SCID) [30], under supervision by a participating cen-
tre PI or nominated deputy, to exclude those who are at
significant risk of self-harm and those with psychiatric
exclusions listed in the Oxford diagnostic criteria for CFS
[2].
3. Patients who are considered by the RN, in discussion
with their centre leader, to be unable to do one or more of
the trial therapies or to complete all trial measures or for
whom participation in the PACE trial would be inappro-
priate to their clinical needs (e.g. someone with signifi-
cant post-traumatic stress disorder or borderline
personality disorder).
4. Patients who have previously attended a PACE centre
specialist fatigue clinic and received a course of treatment,
from a specialist, considered to be similar to SSMC or any
of the supplementary therapies of APT, CBT, or GET as
delivered in the trial will be excluded from taking part in
the trial.
Screening/Baseline Procedures
Written informed consent will be taken before any trial
related procedure takes place. Therefore PACE will utilise
a two-stage consent/enrolment process. In the first stage
the patient will consent to take part in the eligibility and
baseline assessments and in the second stage the patient
will consent to the full trial including randomisation,
treatment and follow-up assessments. This has the added
advantage of allowing one week's consideration by poten-
tial participants before consenting to the full trial.
Data recording and Case Report Forms
Data will be recorded on Case Report Forms (CRFs). These
will be completed by the patient for the self-report meas-
ures, and all other data will be collected and completed by
the RN. The CRFs  will be checked for completeness and
legibility by the RN before being entered onto the trial
database by a local data manager (DM). Once data has
been entered onto the local database, the data will be
transferred to the senior data manager on the trial who
will compare the hard copy CRFs with the database to
check accuracy. S/he will check all the primary outcome
variables and a randomly chosen 20 percent of the other
variables. All CRFs for the first ten patients randomised
per centre will be double checked. If there are any errors
on primary outcomes, or greater than 1% errors of other
variables, 100% data checks will be completed until the
error rate ceases or drops. The database will not include
the assigned treatments – these will be recorded in a sep-
arate database, in order for the statistician analysing the
data to remain blind to treatment allocation.
Initial screening for eligibility – visit 0 (clinic doctor)
New referrals to the outpatient clinics may be received
from GPs or any other appropriate medical practitioner.
Each clinic doctor will ensure that all consecutive new
outpatients with a clinical diagnosis of CFS/ME are con-
sidered for the trial (i.e. if thought to be eligible they are
told about the trial). Each centre leader will keep a trial
log-book of every new chronic fatigue outpatient referral.
This log book will detail each patient seen, whether or not
they were referred for the trial and the reasons if not.
Where the patient is thought to be suitable by the clinic
doctor (with a CFQ score of 6 or above and an SF-36 score
of 65 or below), and the patient agrees to be assessed for
eligibility, the clinic doctor will forward the patient's con-
tact details to the RN. The clinic doctor will give the
patient the trial Participant Information Sheet. The RN
will contact the patient to arrange the first research visit
(visit 1).
Telephone assessment
The RN will contact patients within 24 hours of receipt of
referral, who have been referred by the clinic doctor for
the PACE trial, by telephone. The RN will check that the
patient has received a Participant Information Sheet from
the clinic doctor, and if they express interest in the trial,
will arrange a date for the patient to attend the first
research assessment interview (visit 1) as soon as possible
(within one week of referral, but not more quickly than 48
hours after receipt of the Participant Information Sheet).
Eligibility assessment and consent for assessment – visit 1
All of the following eligibility criteria must be fulfilled for
the patient to participate:
1. The patient has a clinical diagnosis of CFS [2].
2. The patient does not have treatment needs that would
make participation in the PACE trial inappropriate.
3. The patient is aged 18 years or above.
4. The patient can speak and read English at a level ade-
quate for participation in the trial, as assessed by the RN.
The reasons for this include the need to self-rate written
primary and secondary outcomes using scales that have
not been validated in non-English languages; the need toBMC Neurology 2007, 7:6 http://www.biomedcentral.com/1471-2377/7/6
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receive therapy that can be checked for quality and man-
ual adherence; and the prohibitive cost of providing ther-
apy in more than one language.
5. The Chalder Fatigue Questionnaire score is 6 or more
[27].
6. The SF-36 physical function sub-scale score is 65 or less
[28].
7. The Structured Clinical Interview for DSM-IV (SCID i/
P; non-patient edition with psychotic screen) [30], will be
used to exclude patients with psychiatric exclusions [2]. If
a participant or patient is found to have a current psychi-
atric diagnosis on the SCID, the RN will inform the clinic
doctor. All SCIDs will be audio-recorded for the purposes
of quality control and RN supervision; the supervision
being provided by the centre leader or their nominated
deputy.
8. Patients who are considered by the RN in discussion
with their centre leader to be unable to do one or more of
the trial therapies or to complete all trial measures (travel
expenses will be offered for therapy and research assess-
ments).
9. There is no contra-indication to any of the treatments
that might be provided in the trial.
10. Permission has been obtained to review medical
notes.
In addition, the following assessments will be completed
at baseline visit 1:
1. Participant demographic details will be collected
(including date of birth, age, sex, ethnicity, marital or
partner status, years of education, occupation)
2. Duration of CFS/ME (months)
3. Medical History
4. Co-morbid and current medical conditions
5. Current and specific membership of a self-help group
(specific question)
6. Body Mass Index (BMI) (measure weight in kg and
height in metres)
7. The six-minute walking test [31]
At the end of this visit the RN will give the participant the
further baseline self-report questionnaires to complete at
home and return at visit 2. These questionnaires are as fol-
lows:
1. The Chronic Disease Self-Efficacy measure [32]
2. The Work and Social Adjustment Scale [33]
3. Symptom Interpretation Questionnaire [34]
4. Physical Symptoms (Patient Health Questionnaire;
PHQ-15) [35]
5. Exercise and Activity scale [36]
6. Jenkins Sleep Scale of subjective sleep problems [37]
7. The Hospital Anxiety and Depression Scale (HADS)
[38]
8. The EuroQOL (EQ-5D) [39]
9. The RN will also fit the actometer [18] to the patient
with an appropriate explanation and ask them to wear it
until return on visit 2 or for one week (whichever is soon-
est). After visit 1 the research nurse will discuss the
patient's potential eligibility with the centre leader.
Eligibility assessment and consent for trial – visit 2
At visit 2 to the RN (after one week) the patient will return
the actigraphy watch. If the patient meets all of the eligi-
bility criteria and none of the exclusion criteria, under-
stands the purpose of the trial and is willing to give
informed consent to be randomised, treated and followed
up, they will then sign the second consent form to partic-
ipate in the full trial.
Completion of baseline assessment
The following baseline assessments will be completed at
visit 2:
1. Current medications and therapies (including comple-
mentary and alternative treatments)
2. The CDC criteria for CFS [1]
3. The London criteria for myalgic encephalomyelitis [40]
4. Presence or absence of fibromyalgia (using chronic
widespread pain criteria only and not tender points) [41]
5. Preferred treatment group (single question)
6. The Client Service Receipt Inventory (CSRI), adapted
for use in CFS/ME [42]BMC Neurology 2007, 7:6 http://www.biomedcentral.com/1471-2377/7/6
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7. The self-paced step test of fitness [43]
8. The Borg Scale of perceived physical exertion, scored
once immediately after the step test [44]
9. The actigraphy watch will be removed and the actigra-
phy data [18] (as initiated at visit 1 with the research
nurse) will be downloaded.
Randomisation and Enrolment procedure
Participants will be allocated to one of the four trial arms
(ratio 1:1:1:1) by the Mental Health & Neuroscience Clin-
ical Trials Unit (MH&N CTU) based at the Institute of Psy-
chiatry. Allocation will be stratified by centre, CDC Criteria
(met or unmet), London Criteria (met or unmet) and
depressive disorder (major, minor depressive episode and
dysthymia being present or absent) using minimisation
with a random component [45]. The stratification on
these criteria is to ensure equal proportions in each treat-
ment arm. The first N cases (N will not be disclosed) will
be allocated using simple randomisation to further
enhance allocation concealment.
Once an eligible participant has completed the baseline
assessment and given written informed consent, the RN
will contact the MH&N CTU for treatment allocation by
facsimile, giving the criteria needed for randomisation.
Minimisation is carried out with a random component
using a customised Microsoft Access database which will
be used to hold the basic details collected to facilitate sub-
sequent verification and to generate the allocation. Alloca-
tion is concealed because an independent group are
responsible for this allocation. The confirmation of strati-
fication details and treatment allocation will be commu-
nicated by email or facsimile to the RN within 24 hours.
The RN sends back an acknowledgement of receipt to the
CTU. This whole procedure is kept independent and sep-
arate from the trial statisticians. The RN will on the same
day inform the participant of his/her treatment group in
person or by phone, and will also inform the SSMC doctor
and appropriate therapist. The therapist will contact the
participant to arrange the first treatment appointment as
soon as possible (within 5 working days). The SSMC doc-
tor will also arrange to see the participant within one
month of treatment allocation. The individual assign-
ments will be available to the local team on a need-to-
know basis, with the exception of the trial statisticians.
Participant Identification Number
The participant identification number (PIN) will be a five
digit number whereby the first two digits denote the cen-
tre and the remaining three denote the participant
number by centre allocated in order of the patient enter-
ing the screening phase. Therefore every patient who con-
sents to baseline and eligibility assessment will have a
PIN, but not all will be randomised due to some being
ineligible or not giving further consent.
Randomised treatments
Apart from those receiving SSMC alone, all participants
will be offered equal therapist time; 90 minutes in the first
session, and 14 subsequent sessions of 50 minutes. The
15th session will be a "booster" session given at week 36,
thirteen weeks after the 14th session, itself given at 23
weeks, which will be the last week for therapy. Therapy
sessions 2 to 15 need not last the full 50 minutes if not
required. If both therapist and participant believe that the
next planned session is redundant because therapy is
going so well, the next session may be omitted, with a
note made as to the reasons why.
If the participant is unable to attend an appointment in
person (e.g. due to feeling too disabled or due to intercur-
rent ill-health), and this cannot be re-arranged within five
working days, and if agreed by both the therapist and par-
ticipant, this session may be held over the telephone
either at the pre-arranged time or within five working days
of the original appointment. If the session does not take
place within this time, the visit will be recorded as a DNA
(Did Not Attend). Ideally, no more than four sessions of
the first 14 sessions should be held in this way, and they
should not be sequential. However, we believe it would be
better that the participant receives some therapy rather
than none at all and this will be judged on a per-partici-
pant basis. For this reason, if the choice is between not
holding a session and a telephone session, a telephone
session will always be offered even if there already have
been four telephone sessions. This policy is supported by
the results of one RCT and an open trial having suggested
that two of the therapies (CBT and GET) delivered by tel-
ephone sessions following a face to face initial assessment
is efficacious [46,47]. The fifteenth session will be held
face-to-face, if at all possible, but even this may be held by
telephone if the alternative is non-attendance.
We have chosen 15 sessions for all supplementary treat-
ments on the basis of the previous trials of CBT and GET
[18,23-26], as well as extensive clinical experience. RCTs
of the least effective CBT and GET trials used 6 and 8 ses-
sions [25,48]. Although one study of a pragmatic rehabil-
itation found that only 4 sessions were helpful [47], we
suspect that this result may have been related to the lack
of a 'treatment as usual' control group, and that more than
four sessions are necessary to achieve change. A two year
follow-up of this trial showed that the maximal face-to-
face intervention had better efficacy by this time [19]. All
interventions will be based on manuals, revised following
feedback from both patients and therapists after piloting
the manuals and therapies on patients outside of the trial.BMC Neurology 2007, 7:6 http://www.biomedcentral.com/1471-2377/7/6
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Adaptive Pacing Therapy
APT will be based on the illness model of CFS/ME as a cur-
rently undetermined organic disease, with the assumption
that APT can improve quality of life, although not affect
the core disease, other than providing the best conditions
for natural recovery. APT is essentially an energy manage-
ment approach, which involves assessment of the link
between activity and subsequent symptoms and disabil-
ity, establishing a stable baseline of activity using a daily
diary, with advice to plan and pace activity in order to
avoid exacerbations. Strategies include developing aware-
ness of early warning of exacerbations; limiting demands;
regular planned rest and relaxation, and alternating of dif-
ferent sorts of activities. The aim is to achieve optimal
adaptation to the illness [4,16,17]. The patient charity
Action for M.E. have helped in the design of the APT man-
ual and have endorsed this version of pacing, which is
based on what is published and what patients and clini-
cians have reported as helpful. Both therapists and partic-
ipants will receive separate manuals.
Cognitive Behaviour Therapy
CBT will be based on the illness model of fear avoidance,
used in the three positive trials of CBT [18,25,26]. There
are three essential elements: (a) Assessment of illness
beliefs and coping strategies, (b) structuring of daily rest,
sleep and activity, to establish a stable baseline of general
activities, with a graduated return to normal activity, (c)
collaborative challenging of unhelpful beliefs about
symptoms and activity. Both therapists and participants
will receive separate manuals.
Graded Exercise Therapy
GET will be based on the illness model of deconditioning
and exercise intolerance, used in the previous trials
[23,24,47]. Therapy involves an assessment of physical
capacity, establishing a stable baseline level of physical
activity, negotiation of an individually designed home
exercise programme with set target heart rates and times,
and participant feedback with mutual planning of the
next fortnight's exercise programme. Both therapists and
participants will receive separate manuals.
Standardised Specialist Medical Care
SSMC will be given to all participants. This will include
visits to the clinic doctor with general, but not specific
advice, regarding activity and rest management, such as
advice to avoid the extremes of exercise and rest, as well as
pharmacotherapy for specific symptoms and comorbid
conditions. SSMC is standardised in the SSMC Doctor's
Manual. As well as this, SSMC participants, like all other
participants, will already have received the Patient Clinic
Leaflet (PCL). The PCL is a generic leaflet explaining what
CFS/ME is, its likely causes, and available treatments.
There will be no additional therapist involvement. In par-
ticular there will be no diary monitoring with consequent
advice. The number of SSMC outpatient sessions will be
recorded, along with any treatments given for each partic-
ipant by the SSMC doctor. Participants will be seen by
their SSMC doctor a minimum of three times after ran-
domisation, with the first SSMC appointment taking place
as soon as possible after randomisation, and within one
month. Further sessions will be determined by clinical
need. Trial therapists, participants and general practition-
ers can request an unplanned clinical review by the SSMC
doctor.
Departures from randomised treatment
We will use the following strategies to minimise missing
data in primary outcomes. Participants who drop out of
treatment will be assessed as soon as possible, rather than
waiting for the normal follow-up. Those who cannot
attend clinic will be offered home assessments by the RN
(or failing this assessment by telephone or by post), or
centre leader as appropriate. If that is not achieved, we will
seek to obtain outcome data by use of either postal or e-
mail questionnaires, supplemented by telephone calls if
necessary.
DNAs from treatment
The therapist (if they have one) or SSMC doctor will con-
tact the participant by telephone in the first instance to
ascertain the problem of attendance, and will discuss the
appropriate solution with the participant. Choices include
a telephone session or a re-arranged face-to-face session,
so long as the latter is within five working days. Alterna-
tively the session stays a DNA and is recorded as such. If
the participant considers that they are deteriorating the
policy for this problem will be enacted.
Clinician/Researcher withdrawal of participant from 
treatment
The reason for this will be recorded. When this occurs, the
centre leader or nominee should assess the participant
clinically within a week, and arrange appropriate care.
Every effort will be made to obtain the two primary out-
comes and the CGI (to assess illness progression), which
should be scored in order to provide some outcome data.
Such participants' data will be included in the trial analy-
sis. If the participant will still consent to research (RN) fol-
low-up, this will continue as normal.
Participant withdrawal of consent to randomised 
treatment
In the first instance, the therapist (if they have one) or
SSMC doctor will contact the participant by telephone to
ascertain the reason for drop-out, if the participant is will-
ing to share this, and will discuss the appropriate solution
with the participant and then the centre leader. If the par-
ticipant considers that they are deteriorating, but does notBMC Neurology 2007, 7:6 http://www.biomedcentral.com/1471-2377/7/6
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wish to talk to the therapist or SSMC doctor, the centre
leader or nominee should contact them themselves.
If possible, the reason for withdrawal (e.g. adverse events,
intercurrent illness, illness progression, inability to
adhere, inability to attend regularly for treatment or
assessment) should be ascertained. This information will
be passed on to the other relevant members of the team
and the trial manager (TM). The centre leader will ensure
that every effort is made to obtain the primary outcome
measures and the Clinical Global Impression (CGI)
change score [49] from participants who drop out of treat-
ment as soon as this occurs, even if they are not dropping
out of the trial follow-up itself.
The centre leader or nominee will also ascertain whether
consent is withdrawn from further trial treatment only or
from both trial treatment and follow-up and in the latter
case, whether the participant has given permission to
retain data collected before treatment withdrawal for use
at final analysis.
Participant withdrawal of consent to research follow-up
If a participant withdraws consent for research (RN) fol-
low-up during the trial, the centre leader or nominee
should be informed on the same day, if possible. The cen-
tre leader or nominee will then contact the participant to
find out why the participant wishes to withdraw from
research follow-up, if they are willing to give a reason. The
centre leader or nominee will also determine whether the
participant has given permission to retain data collected
before withdrawal for use at final analysis, or whether this
information should be destroyed. No data from the latter
participant will be used in analysis.
Loss to follow-up
Permission will be sought from the Office of National Sta-
tistics (ONS) in England and the Information and Statis-
tics Division (ISD) in Scotland, to track all participants
randomised using NHS numbers. If a participant is lost to
follow-up, the participant's GP will be contacted in the
first instance, and if the participant has moved from the
area, ONS (or ISD) will be contacted for details of the par-
ticipant's new GP. This will only occur if the participant
has given explicit consent (as detailed on the consent
form) to allow this.
In all these situations the centre leader should inform the
general practitioner and any referring doctor that their
patient has withdrawn from either the trial or the trial
treatment.
Measures of treatment compliance/adherence
The SSMC doctor will record how many clinic outpatient
sessions were attended, and how many were not attended
during the 52 weeks by reviewing the medical notes.
If the participant has been receiving supplementary ther-
apy, the therapist will record how many sessions/part ses-
sions out of 15 were attended; whether they were face-to-
face or telephone consultations and the durations of each
session attended. At the end of therapy, the therapist will
also score how well the participant adhered to the general
therapy approach.
Modification of trial treatment
Trial treatments will only be modified with the advice of
the TSC, having been advised by the DMEC that a partic-
ular treatment arm is causing a consistent pattern of dete-
rioration, or if there is another obvious and significant
clinical necessity. The MREC will also need to approve any
change in treatment.
Additional therapy after the trial
Participants who are judged to require further therapy
after their involvement in the trial has been completed,
will be offered additional therapy. The choice of addi-
tional therapy will be agreed by the participant, clinic doc-
tor and relevant therapist, and will start after the final
follow-up interview (52 weeks after randomisation into
the trial).
Absence of a therapist
There will be occasions throughout the course of the trial
when a therapist is absent due to annual leave, sickness,
maternity leave or resignation. In these instances treat-
ment delivery will be modified in order that a partici-
pant's therapy and the trial may continue uninterrupted.
Three contingency plans have been devised to allow for a
flexible approach to tackling this situation when it arises.
Therapy from a nearby centre
Local centre cover is delivered by a PACE therapist of the
same discipline working in a nearby PACE centre.
Distant combined therapy
Distant therapy is delivered by a PACE therapist of the
same discipline, whereby the therapist will conduct some
visits face-to-face and the remainder by telephone. The
participant at the same time may also be treated by a local
cross-cover PACE therapist.
Local cross-cover therapy
Cross-cover therapy is delivered by a PACE therapist of a
different discipline, whereby the cross-cover therapist
learns a second PACE therapy to a competent level. They
are supervised both by a distant centre PACE therapist ofBMC Neurology 2007, 7:6 http://www.biomedcentral.com/1471-2377/7/6
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the appropriate discipline and a local therapist of the
same discipline providing emergency assistance and
assessment in case the patient has an intercurrent problem
(e.g. pulls a muscle during GET).
Recruitment of a new therapist
In the case of resignation or maternity leave, the collabo-
rating centre will seek to recruit a replacement therapist as
quickly as possible.
It is recognised that there is a shortage of therapists work-
ing in the NHS and for this reason, the recruitment of staff
of alternative appropriately qualified disciplines may also
be considered. For example, an exercise physiologist may
be recruited in place of a physiotherapist to deliver GET.
There have been two randomised controlled trials of GET
for CFS/ME provided by exercise physiologists, with posi-
tive outcomes [23,50]. In these instances the therapist will
operate as a 'physiotherapy assistant' to a supervising
physiotherapist. Similar alternative disciplines and super-
vision arrangements may also be considered for APT and
CBT.
Changes to consent process
If a participant is to receive treatment from a therapist of
either a different centre or a different discipline, the par-
ticipant will give additional informed consent once it is
clear that they understand this and are willing to receive
their treatment in this way.
Assessments and Procedures
Assessments
All participants will usually be assessed at the hospital.
Those participants who cannot attend clinic will be
offered home assessments (or failing this assessment by
telephone or by post). Before the second and consequent
RN assessments, self-rated measures will be posted to the
participant prior to the visit and checked for completion
at assessment by the RN. If a participant becomes too tired
or ill to continue with the assessment, they will be offered
the opportunity to complete the assessment on another
day, within the next seven days.
Because we do not think it practically possible for the RN
to remain blind to treatment group allocation, we will not
attempt to achieve this. All our primary and secondary
outcomes are therefore either self-rated or objective in
order to minimise observer bias. Participants who drop
out of treatment will be assessed for outcomes as soon as
possible, rather than waiting for the normal follow-up.
When the participant does not attend a research interview,
the RN should send the self-rated questionnaires to the
participant's home address, with a stamped addressed
envelope. If questionnaires are not received back within a
week, the RN should arrange to visit the participant at
home and oversee completion of the questionnaires. If
necessary, only the primary outcomes and the CGI [49]
(to assess deterioration) should be the minimum com-
pleted.
Long term follow-up
Permission will be sought from the participant to be con-
tacted annually for follow-up information regarding the
participant's health and employment status. The partici-
pant will also be invited to remain in contact so that the
results may be disseminated to them once published.
Measures
Primary outcome measures – Primary efficacy measures
Since we are interested in changes in both symptoms and
disability we have chosen to designate both the symptoms
of fatigue and physical function as primary outcomes.
This is because it is possible that a specific treatment may
relieve symptoms without reducing disability, or vice
versa. Both these measures will be self-rated.
The 11 item Chalder Fatigue Questionnaire measures the
severity of symptomatic fatigue [27], and has been the
most frequently used measure of fatigue in most previous
trials of these interventions. We will use the 0,0,1,1 item
scores to allow a possible score of between 0 and 11. A
positive outcome will be a 50% reduction in fatigue score,
or a score of 3 or less, this threshold having been previ-
ously shown to indicate normal fatigue [27].
The SF-36 physical function sub-scale [29] measures phys-
ical function, and has often been used as a primary out-
come measure in trials of CBT and GET. We will count a
score of 75 (out of a maximum of 100) or more, or a 50%
increase from baseline in SF-36 sub-scale score as a posi-
tive outcome. A score of 70 is about one standard devia-
tion below the mean score (about 85, depending on the
study) for the UK adult population [51,52].
Those participants who improve in both primary outcome
measures will be regarded as overall improvers.
Secondary outcome measures – Secondary efficacy measures
1. The Chalder Fatigue Questionnaire Likert scoring
(0,1,2,3) will be used to compare responses to treatment
[27].
2. The self-rated Clinical Global Impression (CGI) change
score (range 1 – 7) provides a self-rated global measure of
change, and has been used in previous trials [45]. As in
previous trials, we will consider scores of 1 or 2 as a posi-
tive outcome ("very much better" and "much better") and
the rest as non-improvement [23].BMC Neurology 2007, 7:6 http://www.biomedcentral.com/1471-2377/7/6
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3. The CGI change scale will also be rated by the treating
therapist at the end of session number 14, and by the
SSMC doctor at the 52-week review.
4. "Recovery" will be defined by meeting all four of the
following criteria: (i) a Chalder Fatigue Questionnaire
score of 3 or less [27], (ii) SF-36 physical Function score
of 85 or above [47,48], (iii) a CGI score of 1 [45], and (iv)
the participant no longer meets Oxford criteria for CFS
[2], CDC criteria for CFS [1] or the London criteria for ME
[40].
5. The Hospital Anxiety and Depression Scale scores in
both anxiety and depression sub-scales [38].
6. The Work and Social Adjustment scale provides a more
comprehensive measure of participation in occupational
and domestic activities [33].
7. The EuroQOL (EQ-5D) provides a global measure of
the quality of life [39].
8. The six-minute walking test will give an objective out-
come measure of physical capacity [31].
9. The self-paced step test of fitness [43].
10. The Borg Scale of perceived physical exertion [44], to
measure effort with exercise and completed immediately
after the step test.
11. The Client Service Receipt Inventory (CSRI), adapted
for use in CFS/ME [31], will measure hours of employ-
ment/study, wages and benefits received, allowing
another more objective measure of function.
12. An operationalised Likert scale of the nine CDC symp-
toms of CFS [1].
13. The Physical Symptoms (Physical Health Question-
naire 15 items(PHQ15)) [35].
14. A measurement of participant satisfaction with the
trial will also be taken at 52 weeks [53].
Adverse outcomes
Adverse outcomes (score of 5–7 of the self-rated CGI) will
be monitored by examining the CGI at all follow-up
assessment interviews [49]. An adverse outcome will be
considered to have occurred if the physical function score
of the SF-36 [28] has dropped by 20 points from the pre-
vious measurement. This deterioration score has been
chosen since it represents approximately one standard
deviation from the mean baseline scores (between 18 and
27) from previous trials using this measure [23,25]. Fur-
thermore, the RN will enquire regarding specific adverse




3. Duration of CFS/ME (months)
4. 1 week of actigraphy [18] (as initiated at visit 1 with the
research nurse)
5. Body mass index (measure weight in kg and height in
metres)
6. The CDC criteria for CFS [1]
7. The London criteria for myalgic encephalomyelitis [40]
8. Presence or absence of "fibromyalgia" [41]
9. Jenkins sleep scale of subjective sleep problems [37]
10. Symptom interpretation questionnaire [34]
11. Preferred treatment group
12. Self-efficacy for managing chronic disease scale [32]
13. Somatisation (from 15 item physical symptoms PHQ
sub-scale) [35]
14. Depressive disorder (major and minor depressive dis-
order, dysthymia by DSMIV) (from SCID) [30]
15. The Hospital Anxiety and Depression Scale (HADS)
[38] combined score
16. Receipt of ill-health benefits or pension
17. In dispute/negotiation of benefits or pension
18. Current and specific membership of a self-help group
(specific question)
Process variables
1. Step test of fitness [43]
2. Borg Scale of perceived physical exertion [44]
3. The symptom interpretation questionnaire [34]
4. Exercise and activity scaleBMC Neurology 2007, 7:6 http://www.biomedcentral.com/1471-2377/7/6
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5. PHQ symptom sub-scale
6. HADS scale combined score
Therapeutic input
1. At each RN assessment participants will be asked what
other treatments they have been receiving (e.g. comple-
mentary and alternative therapies, prescribed and over-
the-counter medicines).
2. The strength of the therapeutic alliance will be meas-
ured by the therapy integrity rating scale by an independ-
ent and blinded observer [53].
3. The differentiation of the supplementary therapies will
be measured blind to treatment group by an independent
observer [53].
Plausibility of therapy
After the first treatment session, all participants will be
asked to fill in a brief measure of how plausible their treat-
ment appears to them.
Economic costs
The CSRI [42] will retrospectively record service utilisa-
tion for the six months prior to the baseline assessment,
for the period between baseline and 24 weeks, and then
for the period from 24 weeks to 52 weeks. A comprehen-
sive range of services will be included so that in addition
to being able to determine the resource implications to
the NHS, we will also have information on the impact that
treatment has on other parts of the care system as well as
on informal carers. The ability to engage in employment,
education and work in the home are frequently affected
by CFS/ME and the CSRI will collect data on these activi-
ties. Service use will be valued by attaching appropriate
unit costs from national sources (e.g. Netten et al, 2003
[54]) as well as intervention costs specifically calculated
for the study.
Adverse Events
Adverse events (AE) are any clinical change, disease or dis-
order experienced by the participant during their partici-
pation in the trial, whether or not considered related to
the use of treatments being studied in the trial.
Serious Adverse Events (SAEs)
A Serious Adverse Event will be defined according to usual
clinical trial definitions and will be reported to the appro-
priate authorities in the standard manner. If there is any
doubt in the minds of the RN and the centre leader as to
whether the AE is a serious AE, the centre leader will
obtain a second opinion from one of the PIs.
Serious Adverse Reactions (SARs)
A Serious Adverse Reaction can be defined as: An SAE that
is considered to be a reaction to one of the supplementary
therapies or a drug prescribed as part of SSMC.
Reporting serious adverse events and reactions (SAEs and SARs)
In the event of an adverse event (AE), the centre leader or
nominee will judge the seriousness of the event, the rela-
tionship to a trial supplementary therapy or SSMC pre-
scribed treatment, clinical severity and the expectedness of
the event. All SAEs must be reported by the RN to the
SSMC doctor (or SSMC doctor to the RN), centre leader or
nominee (e.g. another centre leader), and the trial man-
ager immediately the RN or SSMC doctor learns of the
SAE, regardless of the relationship to trial treatment.
Reporting of SAEs and SARs will be carried out according
to normal regulatory requirements.
Non-serious adverse events and reactions
Non-serious adverse events or reactions will be assessed
by the RN at each follow-up assessment interview. A risk
assessment has been undertaken, and we have concluded
that the therapies are of low risk to participants. Non-seri-
ous adverse events will be reported according to the usual
regulatory requirements.
Follow-up after adverse events
After an SAE or SAR, a decision will be made by the centre
leader as to whether the participant should be withdrawn
from either their randomised treatment or from the trial,
or need an alteration in their SSMC. Arrangements will be
made by the centre leader for further assessment and man-
agement as required. Advice from the participant's GP,
other health professionals or relevant local authorities
will be sought for any instance of an SAE or SAR where
further external advice is required. The RN will provide the
centre leader and TM with a one month follow-up report
on all SAEs and SARs. Further monthly reports should be
provided in the absence of resolution. These reports will
be communicated to the DMEC and MREC via the TM or
trial statistician, and by the RN to the local Research and
Development (R&D) office.
Safety of participants
There is a discrepancy between patient organisation
reports of the safety of CBT and GET and the published
evidence of minimal risk from RCTs. Surveys by Action for
M.E. of its members suggest that people becoming worse
with these treatments is caused by either rigidly applied
programmes that are not tailored to the patient's disabil-
ity, or by improperly supervised programmes [13-15].
PACE treatment manuals minimize this risk by being
based on mutually agreed and flexible programmes that
vary according to the patient's response. The RN will also
carefully monitor for any adverse effects of the treatments.BMC Neurology 2007, 7:6 http://www.biomedcentral.com/1471-2377/7/6
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Policy for deteriorating participant or one who drops out of treatment
The following policy will be enacted by the centre leader
for any participant who is considered, or considers them-
selves, to be deteriorating, or has dropped out of treat-
ment. The centre leader or delegated professional will
undertake a detailed clinical assessment, at home if neces-
sary, following which they will be offered appropriate
help.
Recruitment, randomisation and retention
The right of the patient to refuse to participate in the trial
without giving reasons must be respected. Those recruit-
ing and randomising participants will rigorously maintain
a position of equipoise and employ explanations that are
consistent with this [55]. All the participating clinicians
regard all the four treatments as potentially effective and
are of the view that most patients seen will accept ran-
domisation if it is fully and openly explained. Some
patients are initially sceptical about treatment effective-
ness but are willing to accept any of these recommended
treatments as long the treatment is appropriately
explained and delivered. Therefore, we do not anticipate a
difficulty either in acceptability of the proposed treat-
ments, with recruitment into the trial, or acceptance of
randomisation. We emphasise that we make this state-
ment based on our having completed six trials of treat-
ment for CFS/ME. After the patient has entered the trial,
the clinic doctor must remain free to give alternative treat-
ment to that specified in the protocol, at any stage, if he/
she feels it to be in the best interest of the patient.
Compliance
The trial will be conducted in compliance with the Decla-
ration of Helsinki, the trial protocol, MRC Good Clinical
Practice (GCP) guidance, the Data Protection Act (1998),
the Multi-centre Research Ethics Committee (MREC) and
Local Research Ethics Committees (LREC) approvals and
other regulatory requirements, as appropriate. The final
trial publication will include all items recommended
under CONSORT.
Sponsor
The main sponsor is Barts and the London, Queen Mary
School of Medicine and Dentistry.
Name of person/s authorised to sign the final protocol and protocol 
amendments for the sponsor
￿ Chair of the Trial Steering Committee, Professor Janet
Darbyshire.
￿ Professor Stephen Stansfeld (on behalf of the Sponsor).
￿ The three principal investigators.
Research Ethics Approval (MREC)
Ethical approval for the PACE trial was given by the West
Midlands MREC (reference number MREC/02/7/89).
Local REC approvals have been sought and obtained as
required.
Indemnity
Each centre taking part in the trial will seek local approval
and indemnity through their NHS R&D department. As an
automatic consequence of this, local NHS indemnity will
apply to the PACE trial. Details of local indemnity




The existing evidence does not allow precise estimates of
improvement with the trial treatments. However the avail-
able data suggests that at one year follow up, 50 to 63% of
participants with CFS/ME had a positive outcome, by
intention to treat, in the three RCTs of rehabilitative CBT
[18,25,26], with 69% improved after an educational reha-
bilitation that closely resembled CBT [43]. This compares
to 18 and 63% improved in the two RCTs of GET [23,24],
and 47% improvement in a clinical audit of GET [56].
Having usual rather than specialist medical care allowed
6% to 17% to improve by one year in two RCTs [18,25].
There are no previous RCTs of APT to guide us [11,12], but
we estimate that APT will be at least as effective as the con-
trol treatments of relaxation and flexibility used in previ-
ous RCTs, with 26% to 27% improved on primary
outcomes [23,26]. We propose that a clinically important
difference would be between 2 and 3 times the improve-
ment rate of SSMC.
Power analyses
Our planned intention to treat analyses will compare APT
against SSMC alone, and both CBT and GET against APT.
Assuming α = 5% and a power of 90%, we require a min-
imum of 135 participants in the SSMC alone and APT
groups, 80 participants in the GET group and 40 in the
CBT group [57]. However these last two numbers are
insufficient to study predictors, process, or cost-effective-
ness. We will not be able to get a precise estimate of the
difference between CBT and GET, though our estimates
will be useful in planning future trials. As an example, to
detect a difference in response rates of 50% and 60%, with
90% power, would require 520 participants per group;
numbers beyond a realistic two-arm trial. Therefore, we
will study equal numbers of 135 participants in each of
the four arms, which gives us greater than 90% power to
study differences in efficacy between APT and both CBT
and GET. We will adjust our numbers for dropouts, at the
same time as designing the trial and its management to
minimise dropouts. Dropout rates were 12 and 33% inBMC Neurology 2007, 7:6 http://www.biomedcentral.com/1471-2377/7/6
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the two studies of GET [23,24] and 3, 10, and 40% in the
three studies of rehabilitative CBT [18,25,26]. On the
basis of our own previous trials, we estimate a dropout
rate of 10%. We therefore require approximately 150 par-
ticipants in each treatment group, or 600 participants in
all. Calculation of the sample size required to detect eco-
nomic differences between treatment groups requires data
of cost per change in outcome, which is not currently
available.
Unblinding
All research and therapy staff and participants are
unblinded to treatment allocation of individual partici-
pants. Therefore there will be no need for unblinding dur-
ing the trial. The one exception is the trial statisticians
who are blind to treatment allocation (coded A, B, C, D),
as will be the DMEC, in order to take actions on the basis
of the unblinded data alone.
Analysis plan
A full Analysis Strategy will be developed, independently
of looking at the trial database, and before undertaking
any analysis. This paper summarises the analysis plan.
Primary analyses of efficacy
The primary analysis will be pragmatic, based on inten-
tion to treat, and will utilise all available follow-up data
from all randomised participants. The primary binary out-
comes of response on the fatigue and physical function
sub-scales (comparing proportions with categorical
adverse deterioration with this scale as well) and both and
a combined response with will be analysed by logistic
regression adjusted for centre with contrasts for:
(1) APT vs. SSMC alone,
(2) APT vs. CBT,
(3) APT vs. GET,
(4) Trend across SSMC alone, APT, and CBT/GET com-
bined,
(5) CBT vs. SSMC alone,
(6) GET vs. SSMC alone.
Participants not followed to one year will be classed as
non-responders unless they show a consistent pattern of
outcome across assessments at 10, 24, and 39 weeks or
whenever the last assessment is obtained.
Secondary analyses of efficacy
The secondary continuous outcomes will be analysed by
repeated measures analysis of variance using a linear
mixed model with AR(1) covariance structure, and includ-
ing centre, depressive disorder, CDC and London criteria
and baseline values as covariates. The same contrasts as
those specified for the primary outcomes will be extracted.
A summary measure, the area under the curve, will also be
reported.
A secondary, per protocol, analysis restricted to partici-
pants who complete a minimum of 12 weeks of treatment
(representing the mid point in therapy time), will also be
performed.
Further secondary sensitivity analyses will be used to
assess the robustness of conclusions for missing primary
outcomes; these will employ repeated binary outcomes,
multiple imputation, and imputation analysing all possi-
ble outcomes [58].
Loss to follow-up, departures from randomised treatment
protocols, and the prevalence of serious adverse events,
will be reported at 13, 26, 39, and 52 weeks from ran-
domisation.
Results from all analyses will be summarised as differ-
ences between percentages or means together with 95%
confidence limits (CL). The significance level for all anal-
yses of primary outcome variables will be P = 0.05 (two-
sided); for secondary outcome variables, P = 0.01 (two-
sided) unless profiles of response can be specified in
advance.
Prior to writing the Analysis Strategy a consensus will be
reached on the profiles of response for each secondary
outcome within each of the four treatment groups.
Predictions and process of treatment
Associations between post-treatment outcomes and both
predictor and process variables (including demographic,
illness duration, and other putative clinical indicators)
will be examined using multiple linear and logistic regres-
sion modelling techniques, including a limited examina-
tion of interactions both amongst pairs of predictors and
between predictors and treatment groups. We anticipate
that the sample size will be sufficient to identify impor-
tant general predictors from a random-split, training set of
two thirds (~400), with partial validation in the remain-
der, used as a test set. Shrinkage techniques (to allow for
over-optimism in variable selection) will be applied in the
development of a prognostic model to be applied to par-
ticipants outside the trial.
Economic analyses
The main economic evaluation will be a cost-effectiveness
analysis conducted from a societal perspective, examining
comprehensive costs (treatment and service costs plus lostBMC Neurology 2007, 7:6 http://www.biomedcentral.com/1471-2377/7/6
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productivity) and the two primary efficacy measures
(fatigue and physical function). Cost-effectiveness accept-
ability curves will be plotted as necessary. A supportive
cost-consequences analysis will be conducted, examining
comprehensive costs alongside all (primary and second-
ary) efficacy measures. To inform special interests, evalua-
tions will also be conducted from the perspectives of the
NHS, and also by using utility scores in the cost-effective-
ness analysis (computed from either the EQ-5D [39] or
the WSAS [33], there being arguments for and against
each as the basis for health-related quality of life measure-
ment).
Monitoring
The principal investigators, centre leaders and participants
will permit trial-related monitoring, audits, ethics com-
mittee review and regulatory inspections by providing
direct access to source data/documents.
Independent overseers
The Data Monitoring and Ethics Committee (DMEC) will
advise on the frequency of reviews of the data on the basis
of accrual and event rates.
The role of the independent Trial Steering Committee
(TSC) is to provide overall supervision for the trial and
safeguard its integrity. Executive authority for the contin-
uation of the trial lies with the TSC.
Confidentiality
All data collected will be regarded as confidential and
securely stored.
Quality assurance and quality control
Quality assurance and control will be ongoing throughout
the trial.
Therapists' compliance with treatment manuals
Therapist compliance with treatment manuals will be
monitored in two ways. 1) All therapists will receive a
minimum of monthly telephone individual supervision
sessions, and face-to-face group and individual supervi-
sion at least four times a year, depending on supervisory
needs. All therapy sessions will be video/audio-recorded.
Some recordings will be used by trainers/supervisors to
provide feedback to therapists on competence and treat-
ment fidelity, which will happen particularly in the first
few months of a therapist starting to treat participants.
Any significant deviations from the manual will be noted
and feedback given to the therapist. Therapist competence
will be measured by the relevant therapy leaders. Thera-
pists will be allowed to treat trial participants once they
have been approved as competent. 2) Two recorded ses-
sions per therapist will be randomly chosen and assessed
blindly and independently by an assessor to assess adher-
ence to manual defined therapy.
SSMC doctors' adherence with SSMC manual
All SSMC doctors will receive training in use of the SSMC
manual. All SSMC sessions will be audiorecorded. Some
recordings will be used by centre leaders (using other cen-
tre leaders when the centre leader is providing SSMC) to
provide feedback to doctors on competence and treat-
ment fidelity, which will happen particularly in the first
few months of a doctor starting to treat participants. Any
significant deviations from the manual will be noted and
feedback given to the doctor. Two recorded sessions per
doctor will be randomly chosen and assessed blindly and
independently by an assessor to assess adherence to man-
ual defined treatment. In addition, this will be particularly
done for any doctor who routinely sees participants more
than five times in the twelve months of the study.
Participant non-adherence with treatment
Participant non-adherence with treatment will be meas-
ured both by recording attendance and by therapist rat-
ings of adherence to therapy.
Database quality
The senior data manager will be responsible for checking
the quality of the Trial Master Database (TMD), and will
send local centre data managers query forms as necessary.
Data Monitoring and Ethics committee
Reports to DMEC and the main analysis itself (as far as
possible) will be compiled blind to allocated treatment.
DMEC reports will simply label treatments as A, B, C or D.
DMEC may request unblinding only if they have serious
concerns about any of the treatments. The unblinding
would be handled by a third statistician independent of
the TMG. The DMEC can recommend premature closure
of the trial to the TSC. The circumstances for this need to
be agreed by the DMEC and TSC, but we suggest the only
likely scenario is if one of the trial treatments is shown to
cause significant and consistent deterioration in a signifi-
cant number of participants (to be quantified at the meet-
ing of the DMEC). If one treatment arm does show
consistent and reliable evidence of causing serious adverse
reactions in participants, then consideration of closing
that particular arm of the trial will be given. The DMEC
will be asked to keep a close eye on any consistent pattern
of deterioration of participants.
Discussion
The PACE trial will be the largest randomised trial of avail-
able treatments for CFS/ME. It will provide important
information about efficacy, adverse events, cost-effective-
ness, process and predictors. This will inform patients,
their carers, healthcare providers and commissionersBMC Neurology 2007, 7:6 http://www.biomedcentral.com/1471-2377/7/6
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which treatments are most useful for which patients, and
provide information regarding the essential process of
both recovery and improvement from CFS/ME.
Current Study Status
The PACE trial opened to recruitment in March 2005.
List of Abbreviations
AE Adverse Event
AfME Action for M.E.
APT Adaptive Pacing Therapy – in this protocol the abbre-
viation 'APT' refers to Adaptive Pacing Therapy given with
Standardised Specialist Medical Care
CBT Cognitive Behaviour Therapy – in this protocol the
abbreviation 'CBT' refers to Cognitive Behaviour Therapy
given with Standardised Specialist Medical Care
CFS Chronic fatigue syndrome
CFS/ME  Chronic fatigue syndrome/myalgic encephalo-
myelitis or encephalopathy – Official term for the illness
as described in the 'Working group report to the Chief
Medical officer' (2002) and the MRC RAG report (2003)
CMO Chief Medical Officer for England
CRF Case Report Form
CSO Chief Scientist's Office for Scotland
CTU Clinical Trials Unit
DM Data Manager
DMEC Data Monitoring and Ethics Committee
DH Department of Health
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DWP Department for Work and Pensions
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GCP Good Clinical Practice
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